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a percentage of all low income households
(n = 704 066). Cumulative proportions for the total
number of sectors and the total population contained
within those sectors were also calculated.
On the basis of these results, if 20% of the most
deprived sectors in Scotland (1 205 833/4 998 202
(24%) of the population) were targeted, 41% of unem›
ployed people and 34% of low income households
would be “captured” (figure). By targeting 254
postcode sectors (1 501 569 (30%) of the population),
resources could be directed to 48% of unemployed
people and 40% of low income households. If 55% of
the postcode sectors are targeted (62% of the popula›
tion), 80% of unemployed people and 74% of low
income households are captured, but even then, 20%
and 26%, respectively, are excluded. Modest improve›
ments in capture rates (2›6%) were achieved when the
analysis was repeated using census enumeration
districts (data not shown).
Comment
This analysis reaffirms Townsend’s argument that the
selective targeting of resources on an area basis would
miss more deprived people than it would include. On
the basis of Carstairs scores, more than 60% of the
population in Scotland would need to be targeted to
include 74% of low income households. The poor sen›
sitivity of an area based approach means that the
group of people to whom resources are directed
includes people who are not poor. There are higher
concentrations of poverty in some areas; however, the
current increase in area based initiatives ignores the
wide spatial distribution of deprived people. Only a
small proportion of government spending is directed
towards area initiatives, but their high profile implies
that deprivation is a problem only within certain areas.
However, deprived areas can include people who are
not deprived and vice versa. Debate continues about
whether the health experience of poor people in
deprived areas is worse than that encountered by other
poor people.5 Targeting deprived areas may have mer›
its, but a greater emphasis on national strategies is the
key to dealing with poverty and improving the health
of the population.
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an earlier draft of the paper.
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Risk of macular degeneration in users of statins:
cross sectional study
Nigel F Hall, Catharine R Gale, Holly Syddall, David I W Phillips, Christopher N Martyn
Atherosclerosis and abnormalities of lipid metabolism
are associated with an increased risk of age related
macular degeneration—the Western world’s main
cause of blindness.1 Statins (hydroxymethyl glutaryl
coenzyme A reductase inhibitors) modify patients’
lipid profile and lower their risk of coronary heart dis›
ease.2 They also prevent stroke and, possibly,
Alzheimer’s disease. We report here an association
between statin use and lower risk of age related macu›
lar degeneration.
Participants, methods, and results
We wrote to 660 men and women aged 66›75 who had
been traced by the Office for National Statistics using
information from their birth record at the Jessop Hos›
pital for Women, Sheffield. Of these, 412 (62%) agreed
to take part and were interviewed at home. We
recorded their use of drugs, including statins, currently
and in the previous five years, and their history of
cardiovascular disease. The participants were invited to
Percentage of areas targeted
Pe
rc
en
ta
ge
 "c
ap
tu
re
d"
0 20 40 60 80 100
0
20
40
60
80
100
Unemployed people
Households with gross annual incomes <£10 000
Spatial equity
Cumulative proportion of unemployed individuals and households
with gross annual incomes <£10 000 in Scotland that would be
captured for each postcode sector if Carstairs scores were used as a
basis for targeting
Papers
Correspondence to:
C N Martyn
cnm@mrc.soton.
ac.uk
continued over
BMJ 2001;323:375–6
375BMJ VOLUME 323 18 AUGUST 2001 bmj.com
a clinic at the Northern General Hospital, Sheffield,
and 392 (95% of those interviewed) attended, where
stereoscopic photos of both fundi were taken.
Photographs were graded by one observer (NFH), who
was unaware of the participants’ drug history, against
standard images using the Wisconsin age related
maculopathy grading system.3 We excluded 12 partici›
pants who had non›age related degenerative macular
changes and one participant who was taking part in a
trial of statins. The analyses that follow are therefore
based on 379 participants.
Of the 379 subjects, 27 (7%) reported taking statins
and 77 (20%) had some evidence of macular degenera›
tion. Age related macular degeneration was more com›
mon among the participants who did not take statins
(see table ): 76/352 (22%) of participants who did not
take statins showed signs of macular degeneration, com›
pared with only 1/27 (4%) of participants taking statins
(P = 0.02, Fisher’s exact test). This is equivalent to an
odds ratio for macular degeneration among participants
who took statins of 0.14 (95% confidence interval 0.02 to
0.83) compared with those who did not.
A history of coronary artery bypass grafting or
angioplasty was associated with macular degeneration.
Eight of the 77 participants with macular degeneration
(10%) had undergone coronary angioplasty or bypass
grafting compared with 13 of the 302 participants (4%)
without macular degeneration (P = 0.05, Fisher’s exact
test). Not surprisingly, people who had undergone
coronary angioplasty or bypass grafting were more
likely to have taken statins than those who had not (6/22
(27%) compared with 21/389 (5%) respectively). In a
logistic regression model—after adjustment for age, sex,
smoking, and history of coronary angioplasty or bypass
grafting—the odds ratio for macular degeneration (early
or late) among participants taking statins was 0.09 (0.01
to 0.73) compared with those who did not take the drug.
Comment
In this survey of men and women aged 66›75 those
who took statins had an eleventh the risk of age related
macular degeneration (after adjustment for coronary
artery disease and smoking) compared with those not
taking the drug. The confidence intervals are wide,
however, giving an imprecise estimate of the reduced
risk. Bias could lead to this association if people with
macular degeneration and taking statins were less
likely to participate, or people without macular degen›
eration and not taking statins were more likely to par›
ticipate, but this seems unlikely.
We suggest three mechanisms that could link statin
use with lower risk of macular degeneration. Firstly,
statins might prevent the accumulation of basal linear
deposit in Bruch’s membrane, which occurs with
higher concentrations of plasma cholesterol.4 Sec›
ondly, antioxidant properties of statins might protect
the outer retina from oxidative damage. Thirdly, sim›
vastatin inhibits endothelial cell apoptosis and
preserves ischaemic vasculature,5 perhaps maintaining
a competent vascular supply to the macula.
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Antenatal detection of HIV: national surveillance and
unlinked anonymous survey
Susan Cliffe, Pat A Tookey, Angus Nicoll
In 1999 national targets were adopted for the univer›
sal offer and recommendation of a test for HIV during
antenatal care throughout England.1 This built on
earlier initiatives aimed at enhancing maternal
diagnosis of HIV infection and reducing perinatal
transmission of HIV with appropriate interventions.2
Substantial improvement in the proportion of mater›
nal HIV infections diagnosed has been reported for
much of London, and improvement has been
observed more recently for the rest of England.3 We
used published estimates of rates of vertical transmis›
sion of HIV in the United Kingdom to assess whether
the target of an 80% reduction in the proportion of
vertically infected infants by December 2002 is likely
to be achieved.1
Participants, methods, and results
We used results from the unlinked anonymous dried
blood spot survey to estimate the number of births in
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Numbers (%) of participants with age related macular
degeneration in either eye by use of statins
Statin use
Age related macular degeneration*
Absent Present
No (n=352) 276 (78.4) 76 (21.6)
Yes (n=27) 26 (96.3) 1 (3.7)†
All (n=379) 302 (79.7) 77 (20.3)
*Early or late age related macular degeneration in either eye as determined by
the Wisconsin age related maculopathy grading system.
†P=0.02 (Fisher’s exact test) for macular degeneration versus none.
Details of methods
are on the BMJ’s
website
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